Introduction {#sec1}
============

In Japan, prostate cancer (PCa) is the fourth most frequently diagnosed malignancy and has been increasing in the past decades ([@ref1]). However, the mortality rate ranks sixth in men and has generally been declining due to improved treatment modalities and the spread of early detection methods for PCa. The 5 year relative survival rate in patients with PCa was 66.8% from 1993 to 1996 and increased to 97.5% from 2006 to 2008; hence, PCa has been recognized as a disease having the most favorable prognosis of common cancers in Japan.

Although more than 70% of PCa patients were diagnosed at a localized stage in Japan and were guaranteed long-term survival by the many treatment options available ([@ref1],[@ref2]), there is little compelling evidence to indicate any difference in efficacy between those treatments ([@ref3]). Therefore, most patients narrow down their choices for treatment based on learning beforehand about possible adverse effects of each procedure ([@ref4]).

A variety of treatments for localized PCa can each cause serious physical, emotional and sexual function damage to patients, which results in a substantial impairment of health-related quality of life (HRQOL) ([@ref5]). Several studies have investigated the impacts on HRQOL of patients with PCa following treatment and have revealed a more significant decline in sexual function following surgery compared with external beam radiation therapy (EBRT) ([@ref6]).

Although proton beam therapy (PBT) is one type of EBRT, proton beams have several features that distinguish them from X-rays, such as a sharp radiation-dose gradient called the Bragg peak, which can minimize damage to surrounding normal tissues and result in better outcomes of HRQOL in patients than that of X-ray ([@ref7]).

Recent studies from the US and Germany showed favorable results on HRQOL of patients with localized PCa in PBT ([@ref10]). However, HRQOL is largely subject to the cultural background and lifestyle of patients and these results may not be applicable to Japanese patients ([@ref19]). Moreover, although there are many studies on HRQOL targeted at Japanese patients with PCa, to the best of our knowledge there have been no reports in Japan on HRQOL after PBT.

The purpose of this study was to investigate patient-reported HRQOL outcomes using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire in a single institutional cohort of patients with localized PCa who received definitive PBT ([@ref19]), and to explore the differences in HRQOL from other treatment modalities for PCa in Japan.

Patients and methods {#sec2}
====================

Patients and study design {#sec3}
-------------------------

Patients who met the following criteria were eligible for the study: (i) pathologically confirmed with prostate biopsy; (ii) no metastasis with computed tomography (CT), bone scintigraphy and magnetic resonance imaging (MRI) and/or positron-emission tomography (PET) within 3 months before treatment; (iii) no prior malignancy within 5 years; (iv) no history of surgery or radiotherapy in pelvis; (v) life expectancy of greater than 5 years with Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

The primary endpoint of the study was HRQOL outcomes of PBT for patients with PCa. The secondary endpoint was the impact of androgen deprivation therapy (ADT) on HRQOL in PCa patients. We considered patients who underwent ADT before treatment as patients with ADT regardless of whether they were involved with ADT following PBT or not.

Between January 2011 and April 2016, 602 consecutive patients with PCa were admitted to our center. Of these, 10 patients who had undergone surgery, 5 who were not Japanese, 2 with bone metastasis, 1 with a history of irradiation and 1 who declined to enter the study were excluded, while the remaining 583 were enrolled on the study.

HRQOL profiles were obtained prospectively with the Japanese EPIC questionnaire before the initiation of treatment (pre-PBT), the last irradiation day of PBT (post-PBT) and every 12 months annually following treatments. The questionnaire was mailed to the patients and returned to us at specified timings. We did not press the patients for reply if there was no response from them.

This study was approved by the institutional review boards (MEDI 10-9 and 16042889), and written informed consent was obtained from all patients prior to enrollment. All procedures were performed in accordance with the ethical standards outlined in the Helsinki Declaration of 1975, as revised in 2000.

Proton beam therapy {#sec4}
-------------------

The gross tumor volume was not indicated for all patients, but the clinical target volume (CTV) was defined as the prostate gland for low- and intermediate-risk patients, and the seminal vesicle was added to the CTV for high-risk patients. The planning target volume was set as the CTV plus 7 mm lateral margins and 10 mm margins in all other directions.

Although we initially performed PBT using 74 Gray Equivalent (GyE) with 37 fractions (fr) for low- and intermediate-risk patients and 78 GyE/39 fr for high-risk patients, a protocol of 70 GyE/28 fr was initiated for all patients in 2013. Patients were all treated with 210 MeV proton horizontal beams, which were produced by a beam-wobbling system for a flatter irradiated field, with a ridge filter (Mitsubishi Electric Corporation, Tokyo, Japan).

All patients were administered magnesium oxide for preventing constipation and with dimethicone for reducing intestinal gas during PBT. Moreover, they were required to defecate 30--60 min before irradiation. The details of simulation, planning and treatment procedures have been previously described ([@ref21]).

Follow-up and evaluation of recurrence {#sec5}
--------------------------------------

All patients were evaluated for prostate-specific antigen (PSA) values, adverse events and disease-related symptoms every 3--6 months by self-referring urologists. Biochemical failure was determined based on the Phoenix definition, and clinical recurrence was decided via imaging modalities such as bone scintigraphy, CT, PET and MRI ([@ref22]). Meanwhile, ADT was left to the self-referring physicians' discretion for all risk group classifications.

Statistical analysis {#sec6}
--------------------

The scores measured via EPIC were calculated according to the instrument instructions ([@ref19],[@ref20]). The scores ranged from 0 to 100, with high scores representing more favorable HRQOL. Statistical analyses were performed with SAS Release 8.2 (SAS Inst., Cary, NC, USA) for these calculated scores. We estimated the least squares means (LSM) and standard errors (SE) for each assessment timing and used them to compare the scores statistically in the same domains and subscales with the randomized block method. A *P* value of \<0.05 was considered statistically significant.

Results {#sec7}
=======

Patient characteristics {#sec8}
-----------------------

The patient characteristics are summarized in [Table 1](#TB1){ref-type="table"}. The patients' median age was 66 (range, 39--88 years). The low-, intermediate- and high-risk groups comprised 72 (12%), 268 (46%) and 243 (42%) patients, respectively. The 70 GyE/28 fr, 74 GyE/37 fr and 78 GyE/39 fr protocols were performed in 307 (53%), 157 (27%) and 119 (20%) patients, respectively. One hundred and ninety-one patients (33%) were administered with ADT before initiation of irradiation. The number of corresponding patients at each assessment timing were 583 (100%) at pre-PBT, 569 (98%) at post-PBT, 474 (81%) at a year, 367 (63%) at 2 years, 247 (42%) at 3 years and 140 (24%) at 4 years after treatment, respectively. Biochemical recurrence, bone-, lymph node- and liver-metastasis and local recurrence were seen in 12 (2.1%), 8 (1.4%), 2 (0.3%), 1 (0.2%) and 1 (0.2%) patients, respectively, during follow-up in the study. There were significant differences between the base-line HRQOL scores obtained from patients with and without ADT on all sexual and hormonal domains (*P* \< 0.01).

###### 

Patient characteristics

  Factors                         Items           Value (unit)
  ------------------------------- --------------- --------------
  No. of patients                                 583
  Age                             Median          66 years
  Range                           39--88 years    
  Risk classification (NCCN)      Low             72 (12%)
  Intermediate                    268 (46%)       
  High                            243 (42%)       
  Protocol (GyE/fraction)         74/37           157 (27%)
  78/39                           119 (20%)       
  70/28                           307 (53%)       
  ADT                             Yes             191 (33%)
  No                              392 (67%)       
  No. of corresponding patients   Pre-treatment   583 (100%)
  Post-treatment                  569 (98%)       
  1 year                          474 (81%)       
  2 years                         367 (63%)       
  3 years                         247 (42%)       
  4 years                         140 (24%)       
  Recurrence                      Biochemical     12 (2.1%)
  Bone                            8 (1.4%)        
  Lymph node                      2 (0.3%)        
  Liver                           1 (0.2%)        
  Prostate                        1 (0.2%)        
  Others                          1 (0.2%)        

No., number; NCCN, National Comprehensive Cancer Network; GyE, Gray Equivalent; ADT, androgen deprivation therapy.

Urinary domain {#sec9}
--------------

Scores of urinary summary and subscales (function, bother, irritative/obstructive and incontinence) are shown in [Table 2](#TB2){ref-type="table"}. There was a significant difference in all scores on urinary parameters between post-PBT and other assessment timings except for incontinence subscale (*P* \< 0.0001). These results demonstrated that there was a substantial decrease in urinary function, bother and irritative/obstructive parameters immediately after PBT and recovery at a year after treatment excluding urinary incontinence.

###### 

Scores on urinary domain

  Assessment time   Summary    Subscale                                                                                                                                                     
  ----------------- ---------- ---------- ----- ---------- ---------- ------ ----- ---------- ---------- ------ ----- ---------- ---------- ------ ----- ---------- ---------- ------ ----- --------
  Pre-PBT           470 (81)   91.5       0.4   --         488 (84)   95.6   0.4   --         471 (81)   88.6   0.5   --         467 (80)   90.6   0.5   --         445 (76)   95.2   0.5   --
  Post-PBT          474 (83)   82.9       0.4   \<0.0001   490 (86)   90.6   0.4   \<0.0001   472 (83)   77.4   0.5   \<0.0001   472 (83)   79.5   0.5   \<0.0001   460 (81)   93.5   0.5   0.5709
  1 year            321 (68)   91.5       0.5   1.0000     326 (69)   95.4   0.5   0.9997     309 (65)   88.7   0.6   1.0000     320 (68)   90.9   0.6   0.9992     317 (67)   94.6   0.6   0.9999
  2 years           208 (57)   91.1       0.6   0.9961     210 (57)   95.7   0.7   1.0000     209 (57)   87.7   0.8   0.9304     207 (56)   90.9   0.8   0.9998     204 (56)   94.2   0.7   0.8677
  3 years           116 (47)   91.6       0.8   1.0000     116 (47)   94.8   0.9   0.9687     116 (47)   89.2   1.0   0.9949     116 (47)   91.6   1.0   0.9573     113 (46)   93.7   1.0   0.9630
  4 years           79 (56)    91.4       1.0   1.0000     79 (56)    96.2   1.1   0.9943     79 (56)    87.9   1.2   0.9947     79 (56)    91.6   1.2   0.9789     78 (56)    93.1   1.2   0.9987

LSM, least squares mean; SE Standard error.

###### 

Scores on bowel, sexual and hormonal domains

  Domain         Assessment time   Summary    Subscale                                                                               
  -------------- ----------------- ---------- ---------- ----- ---------- ---------- ------ ----- ---------- ---------- ------ ----- ----------
  Bowel          Pre-PBT           471 (81)   93.9       0.3   --         485 (83)   92.5   0.3   --         478 (81)   95.3   0.4   --
                 Post-PBT          472 (82)   90.8       0.3   \<0.0001   483 (84)   89.0   0.3   \<0.0001   476 (83)   92.5   0.4   \<0.0001
                 1 year            315 (66)   93.1       0.4   0.6147     322 (67)   91.6   0.4   0.6090     320 (67)   94.6   0.5   0.8440
                 2 years           206 (56)   93.0       0.5   0.5850     209 (56)   92.0   0.6   0.9749     208 (56)   94.0   0.6   0.4067
                 3 years           112 (45)   93.1       0.7   0.8758     114 (46)   92.0   0.8   0.9916     114 (46)   94.3   0.8   0.8391
                 4 years           77 (55)    93.5       0.8   0.9956     78 (55)    91.7   0.9   0.9666     77 (55)    95.2   0.9   1.0000
  Sexual                                                                                                                             
   With ADT      Pre-PBT           143 (74)   32.7       0.7   --         145 (75)   8.7    0.9   --         134 (70)   88.0   1.5   --
                 Post-PBT          144 (77)   32.7       0.7   1.0000     143 (76)   6.1    0.9   0.2504     140 (74)   93.4   1.5   0.9915
                 1 year            99 (64)    31.0       0.8   0.5890     101 (66)   10.0   1.1   0.9470     95 (62)    78.5   1.9   0.0031
                 2 years           57 (48)    31.5       1.1   0.9186     58 (54)    8.7    1.5   1.0000     58 (54)    82.0   2.5   0.3089
                 3 years           32 (40)    29.0       1.4   0.1428     31 (38)    9.1    2.0   1.0000     31 (38)    74.4   3.3   0.0022
                 4 years           19 (46)    32.2       1.9   0.9998     19 (46)    12.3   2.5   0.7421     18 (43)    76.7   4.3   0.1389
   Without ADT   Pre-PBT           318 (80)   48.0       0.6   --         319 (81)   33.5   0.7   --         317 (80)   81.2   1.1   --
                 Post-PBT          322 (84)   43.2       0.6   \<0.0001   322 (84)   25.0   0.7   \<0.0001   314 (82)   84.1   1.1   0.4073
                 1 year            199 (61)   42.3       0.8   \<0.0001   198 (61)   26.7   0.9   \<0.0001   198 (61)   77.2   1.5   0.2751
                 2 years           137 (54)   38.7       1.0   \<0.0001   137 (54)   23.1   1.1   \<0.0001   137 (54)   73.8   1.8   0.0060
                 3 years           80 (47)    38.3       1.3   \<0.0001   76 (44)    22.1   1.5   \<0.0001   79 (46)    75.9   2.4   0.3119
                 4 years           54 (55)    35.6       1.6   \<0.0001   54 (55)    19.3   1.7   \<0.0001   54 (55)    72.3   2.8   0.0379
  Hormonal                                                                                                                           
   With ADT      Pre-PBT           147 (76)   86.6       0.8   --         149 (78)   83.5   1.0   --         145 (75)   89.0   0.7   --
                 Post-PBT          142 (75)   88.3       0.8   0.5327     149 (79)   84.1   1.0   0.9974     142 (75)   91.6   0.8   0.0968
                 1 year            103 (67)   91.8       1.0   0.0006     106 (69)   89.2   1.2   0.0071     103 (67)   93.9   0.9   0.0011
                 2 years           59 (50)    93.6       1.3   \<0.0001   61 (51)    91.3   1.6   0.0007     59 (50)    95.1   1.2   0.0003
                 3 years           32 (40)    95.8       1.7   \<0.0001   31 (38)    93.5   2.2   0.0006     32 (40)    97.6   1.6   \<0.0001
                 4 years           19 (46)    93.3       2.2   0.0430     19 (46)    91.0   2.9   0.1327     19 (46)    94.9   2.1   0.0931
   Without ADT   Pre-PBT           310 (79)   93.8       0.4   --         319 (81)   91.8   0.5   --         314 (80)   95.4   0.4   --
                 Post-PBT          313 (81)   94.4       0.4   0.8480     323 (84)   92.3   0.5   0.9650     318 (83)   96.1   0.4   0.7397
                 1 year            201 (62)   94.4       0.5   0.9327     208 (65)   93.0   0.6   0.6113     204 (63)   95.7   0.5   0.9954
                 2 years           141 (56)   94.5       0.6   0.9024     144 (57)   93.6   0.7   0.3198     142 (84)   95.4   0.6   1.0000
                 3 years           77 (45)    93.1       0.8   0.9623     79 (46)    91.3   1.0   0.9975     78 (46)    95.0   0.8   0.9978
                 4 years           57 (58)    95.1       0.9   0.7494     57 (58)    93.2   1.2   0.8714     57 (58)    96.7   0.9   0.7376

###### 

Comparison with previous reports on HRQOL in the various treatment options for prostate cancer

  Reports                       Year   Treatment                               Patients (number)   Age                                     F/U time (months)                           Dose (Gy)                                   Fraction                                 HRQOL                                  Urinary                   Bowel   Sexual   Hormone                   
  ----------------------------- ------ --------------------------------------- ------------------- --------------------------------------- ------------------------------------------- ------------------------------------------- ---------------------------------------- -------------------------------------- ------------------------- ------- -------- --------- --- --- --- --- ---
  Hashine et al. ([@ref27])     2009   RRP                                     96                  66                                      51--79                                      1--12                                       --                                       --                                     EPIC, SF-8                        ∘                  ∘       ∘       
                                       LDR-BT                                  88                  69                                      52--84                                                                                  145                                      1                                                                                                           
  Yamamoto et al. ([@ref28])    2014   IMRT                                    91                  70                                      56--79                                      3--24                                       70--78                                   35--39                                 EPIC, SF-8, IPSS                  ∘                  ∘       ∘       ∘
  Hashine et al. ([@ref29])     2014   ORP                                     107                 67                                      51--79                                      1--12                                       --                                       --                                     EPIC, SF-8, IPSS                  ∘                  ∘       ∘       
                                       LRP                                     105                 66                                      51--78                                                                                                                                                                                                                                       
  Muramaki et al. ([@ref30])    2014   LRP                                     57                  67[^a^](#tblfn1){ref-type="table-fn"}   61--72[^b^](#tblfn2){ref-type="table-fn"}   16--42[^b^](#tblfn2){ref-type="table-fn"}   --                                       --                                     EPIC, SF-8                ∘       ∘        ∘         ∘   ∘   ∘   ∘   ∘
                                       MIE-RP                                  58                  67[^a^](#tblfn1){ref-type="table-fn"}   62--72[^b^](#tblfn2){ref-type="table-fn"}   16--38[^b^](#tblfn2){ref-type="table-fn"}                                                                                                                                                        
  Hashimoto et al. ([@ref31])   2015   HDR-BT                                  118                 67[^a^](#tblfn1){ref-type="table-fn"}   50--79                                      1--24                                       18                                       2                                      EPIC                      ∘       ∘                                  
                                       EBRT                                                                                                                                                                                        45                                       15                                                                                                          
  Miyake et al. ([@ref32])      2016   RARP                                    298                 66[^a^](#tblfn1){ref-type="table-fn"}   49--79                                      1--24                                       --                                       --                                     EPIC, SF-8                ∘       ∘        ∘         ∘   ∘   ∘   ∘   ∘
  Okihara et al. ([@ref33])     2017   LDR-BT                                  482                 67                                      50--89                                      3--36                                       167[^c^](#tblfn3){ref-type="table-fn"}   1[^c^](#tblfn3){ref-type="table-fn"}   EPIC                                                     ∘   ∘       
  Koike et al. ([@ref34])       2017   RARP                                    105                 66                                      49--79                                      3--12                                       --                                       --                                     EPIC, SF-8                ∘       ∘        ∘         ∘   ∘   ∘   ∘   ∘
                                       LRP                                     229                 68                                      52--78                                                                                                                                                                                                                                       
  Hashine et al. ([@ref35])     2018   LRP                                     105                 66                                      51--78                                      1--36                                                                                                                       EPIC, SF-8, IPSS                  ∘                  ∘       ∘       
                                       RRP                                     107                 67                                      51--79                                                                                                                                                                                                                                       
  Hashimoto et al. ([@ref36])   2018   IMRT                                    195                 74                                      67--76                                      1--24                                       66                                       22                                     EPIC                      ∘                ∘             ∘       ∘   
  Ueno et al. ([@ref37])        2018   RP[^d^](#tblfn4){ref-type="table-fn"}   850                 71                                      67--76                                      3--12                                                                                --                                     EPIC, SF-8                ∘                ∘             ∘       ∘   
                                       ADT                                     370                 73                                      67--76                                                                                                                                                                                                                                       
  Nakai et al. ([@ref38])       2018   IMRT                                    121                 73                                      55--82                                      1--24                                       74--76                                   37--38                                 EPIC, SF-8, IPSS, OABSS   ∘                ∘             ∘       ∘   
  Maruyama et al. ([@ref39])    2019   RARP                                    201                 68                                      63--72                                      1--12                                       --                                       --                                     EPIC                      ∘       ∘        ∘             ∘       ∘   
  Our study                     2019   Proton                                  583                 66                                      39--88                                      2--60                                       70--78                                   28--39                                 EPIC                      ∘       ∘        ∘         ∘   ∘   ∘   ∘   ∘

F/U, follow-up; HRQOL, health-related quality of life; RRP, retropubic radical prostatectomy; LDR-BT, low dose-rate brachytherapy; EPIC, Expanded Prostate Cancer Index Composite; SF-8, medical outcome study 8 items short form health survey; IMRT, intensity-modulated radiation therapy; IPSS, international prostate symptom score; LRP, laparoscopic radical prostatectomy; MIE-RP, minimum incision endoscopic radical prostatectomy; ORP, open radical prostatectomy; HDR-BT, high dose-rate brachytherapy; EBRT, external beam radiation therapy; RARP, robot-assisted radical prostatectomy; RP, radical prostatectomy; ADT, androgen deprivation therapy; OABSS, overactive bladder symptom score.

^a^Mean values.

^b^Time between the maximum and minimum standard deviation values.

^c^Mean value of D90 for prostate in I-125 monotherapy.

^d^Includes retropubic/perineal/laparoscopic/robotic assisted RP.

![The transitions of HRQOL following treatments (Tx): radical retropubic prostatectomy (RRP), laparoscopic radical prostatectomy (LRP), robot-assisted laparoscopic radical prostatectomy (RARP), high dose-rate brachytherapy (HDR-BT) combined with external beam radiation therapy (EBRT), high dose-rate brachytherapy (LDR-BT), intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) in the summary of urinary (a), bowel (b), sexual (c) and hormonal (d) domains and function (e), bother (f), irritative/obstructive (g) and incontinence (h) in the urinary subscales, and bowel function (i) and bother (j), sexual function (k) and bother (l), and hormonal function (m) and bother (n), respectively. The dotted lines represent the existence of missing data.](hyaa027f1){#f1}

Bowel domain {#sec10}
------------

Scores of bowel summary and subscales (function and bother) are shown in [Table 3](#TB3){ref-type="table"}. There was a significant difference in all scores of bowel domain between post-PBT and other assessment timings (*P* \< 0.0001). These results revealed that there was a substantial decrease in bowel function and bother immediately after PBT and recovery at a year after treatment.

Sexual domain {#sec11}
-------------

The scores on sexual summary and subscales (function and bother) are shown in [Table 3](#TB3){ref-type="table"}. Although there was no significant difference in sexual summary and function subscale in patients with ADT between pre- and post-PBT, we found a significant difference between pre-PBT and 1 year (*P* = 0.0031), and also 3 years after PBT (*P* = 0.0022), in sexual bother subscale, respectively.

There was a significant difference in sexual summary and function subscale in patients without ADT between pre-PBT and other assessment timings (*P* \< 0.0001), and also between pre-PBT and 2 years (*P* = 0.0060) and 4 years (*P* = 0.0379) after PBT in sexual bother subscale, respectively.

The scores on sexual function subscale in patients with ADT subsequently remained at low levels for 4 years, whereas those of patients without ADT were clearly higher than those with ADT but decreased year after year. However, the scores on sexual bother subscale in patients both with and without ADT were relatively high and almost similar.

Hormonal domain {#sec12}
---------------

The scores of hormonal summary and subscales (function and bother) are shown in [Table 3](#TB3){ref-type="table"}. There was a significant difference in patients with ADT between pre-PBT and 1 year (*P* = 0.0006)/2 years (*P* \< 0.0001)/3 years (*P* \< 0.0001)/4 years (*P* = 0.0430) after PBT in summary, and 1 year (*P* = 0.0071)/2 years (*P* = 0.0007)/3 years (*P* = 0.0006) after PBT in function subscale, and 1 year (*P* = 0.0011)/2 years (*P* = 0.0003)/3 years (*P* \< 0.0001) after PBT in bother subscale, respectively.

There was no significant difference in any scores on this domain in patients without ADT between pre-PBT and other assessment timings.

The scores on hormonal domain in patients without ADT subsequently remained at a high level; however, those of patients with ADT gradually increased after treatment and were comparable to those of non-ADT patients after about 2 years in every item of this domain.

Discussion {#sec13}
==========

Although PBT has been recognized as one of the definitive treatment modalities for localized PCa in Japan since the national health insurance began coverage of PBT for PCa in April 2018 and we can refer to treatment outcomes on efficacy and adverse events of PBT ([@ref21],[@ref23],[@ref24]), there were no reports available on HRQOL in Japanese patients with PCa who underwent PBT. The HRQOL is subject to the cultural background and lifestyle of patients in the region and country and the information on HRQOL after PBT derived from Western countries may not be applicable to Japanese patients ([@ref19]). Therefore, we thought that it was necessary to investigate HRQOL outcomes in Japanese patients with PCa who received PBT in Japan.

In our study, we examined patients up to a maximum follow-up period of 4 years; however, the number of corresponding patients at 4 years after PBT was 140, which was only 24% of all targeted patients. Moreover, the corresponding rates from those patients at that timing ranged from 46 to 58% as described in [Tables 2](#TB2){ref-type="table"} and [3](#TB3){ref-type="table"}. Therefore, we must highlight the decreased scientific significance of the data for HRQOL at 4 years post-PBT in the study.

The period of ADT can influence the HRQOL of patients with PCa since some adverse events are associated with decreased testosterone due to ADT and may resolve due to the recovery of testosterone after discontinuation of ADT ([@ref25]). However, accurate data from all patients in the study regarding the period of ADT were unavailable; hence we were able to analyze the data based only on the presence or absence of ADT before PBT. Nevertheless, there was a significant difference observed between the base-line HRQOL scores obtained from patients with and without ADT in the study. Therefore, we considered it relevant to present the difference between patients with and without ADT in the PBT despite the insufficiency in the data.

Although the mean and standard deviation of scores were utilized to compare HRQOL outcomes in the several previous studies ([@ref10],[@ref11]), we instead presented the values of LSM and SE obtained statistically with the randomized block method for the purpose of statistical accuracy. This was because uninterrupted follow-up for the entire 4 years of the study, with entirely completed questionnaires, was not attainable for most patients. We did not insist on patients completing the set of questionnaires in the study because of the possibility that the patient would feel uncomfortable and thus provide inaccurate answers ([@ref26]). Nevertheless, we believe that the other available data obtained from their responses should not be ignored nor discarded. Both methods led to identical results with regard to their statistical significances except for some minor variations of *P* values in the study.

[Table 4](#TB4){ref-type="table"} shows the previous results on HRQOL for localized PCa in Japan for various definitive treatment modalities covered by the Japanese national health insurance system. The median age of patients in the study was 66 years, and its range was 39--88 years, the largest range compared with previous studies in Japan. Compared with other studies, the number of patients in the study was the second largest and the follow-up time was the longest. Although we measured HRQOL in PCa patients with only EPIC, all domains and subscales in the evaluation method were investigated in the study.

[Figure 1](#f1){ref-type="fig"} shows the transitions of HRQOL in different treatments for localized PCa in Japan. These diagrams were produced based on published literature as a reference and not based on original data. Age-matching or propensity-matching were not performed on the cohorts in our study; therefore, we cannot directly compare and analyze the results of each treatment modality statistically and academically. The scores before treatment in our study were almost the same as those in other studies, which supports the premise that those patients had a similar cultural and social background.

We selected some principal literature on HRQOL in treatments for patients with PCa in Japan and compared a plurality of graphs in an overlapped manner, which included the following: radical retropubic prostatectomy (RRP) by Hashine et al. ([@ref35]), laparoscopic radical prostatectomy (LRP) by Hashine et al. ([@ref35]), robotic-assisted radical prostatectomy (RARP) by Miyake et al. ([@ref32]), high dose-rate brachytherapy (HDR-BT) plus external beam radiation therapy (EBRT) by Hashimoto et al. ([@ref31]), low dose-rate brachytherapy (LDR-BT) by Okihara et al. ([@ref33]) and intensity-modulated radiation therapy (IMRT) by Hashimoto et al. ([@ref36]), and PBT in the study.

The transitions of scores on urinary summary and subscales in RRP, LRP, RARP, HDR-BT plus EBRT, IMRT and PBT are shown in [Fig. 1(a, e, f, g and h)](#f1){ref-type="fig"}. Our results were almost the same as those of HDR-BT plus EBRT in the urinary domain. The magnitude of decline in scores of urinary function and incontinence subscales after surgery was even larger than those after radiotherapy including HDR-BT plus EBRT, IMRT and PBT, whereas we did not find any substantial differences in transitions of scores on urinary bother and irritative/obstructive subscales among those treatments.

The transitions of scores on bowel domain in RRP, LRP, RARP, IMRT and PBT are shown in [Fig. 1(b, i and j)](#f1){ref-type="fig"}. Although there was a significant difference in all scores of bowel domain between post-PBT and other assessment timings in the study (*P* \< 0.0001), we found that a decline in scores on bowel domain immediately after PBT was too small to register a change on a scale of 0--100 in EPIC and we did not find an obvious trend or difference in those treatment procedures. We consider that these results are mainly attributable to the digestive tract not having been irradiated except for a part of the rectum in both IMRT and PBT ([@ref21],[@ref36]).

The transitions of scores on sexual domain in RRP, LRP, RARP, LDR-BT, IMRT and PBT are shown in [Fig. 1(c, k and l)](#f1){ref-type="fig"}, in which we displayed graphs for only patients without ADT in order to compare the results in each treatment modality. The scores of sexual summary in LDR-BT and PBT decreased in a gradual and similar manner during the observation period, although the decline in scores after RARP was slightly larger than those of the previous two treatment modalities. The low score before treatment in patients who received IMRT by Hashimoto et al. was considered to be influenced by ADT administered before the definitive treatment ([@ref36]). In sexual function subscale, the graphs clearly delineated two groups: one was a radiotherapy group that included LDR-BT and PBT, another was a surgery group that contained LRP, RRP and RARP. The scores on sexual function subscale in the radiotherapy group decreased gradually every year, which indicated a possibility that effects of aging were larger than the impact of radiotherapy in sexual function ([@ref31]). Whereas in the surgery group, the scores dropped markedly after treatments and hovered at low levels in the observation period. Nevertheless, the scores of the surgery group on the sexual bother subscale maintained high levels and were equal to or more than those of the radiation group. These results support a hypothesis that loss of sexual function due to surgery might emancipate patients from sexual bother in contrast to the maintenance of sexual activity with radiotherapy in Japan.

The transitions of scores on hormonal domain in RARP, IMRT and PBT are shown in [Fig. 1(d, m and n)](#f1){ref-type="fig"}. There was little difference in the scores of hormonal summary, function and bother subscales between RARP and PBT in the observation period. On the other hand, the scores on hormonal summary in IMRT were slightly lower than those of the previous two modalities although the difference diminished by 2 years after treatment. This result was considered to be caused by ADT performed before the definitive treatment ([@ref36],[@ref40]).

In conclusion, we investigated patient-reported HRQOL outcomes with EPIC for patients with PCa who underwent definitive PBT and explored the differences in HRQOL between PBT and other treatment modalities in Japan. Although there was little difference in HRQOL between PBT and the other radiation therapies, there were large differences between PBT and various surgical procedures. We believe that our results would be of assistance to Japanese patients with PCa selecting an appropriate treatment procedure, and could also be useful to medical staff advising patients on HRQOL after treatments.
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